Condition category
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Contact information



Primary contact

Miss Louise Handley


Contact details

Liverpool Cancer Trials Unit
Cancer Research UK Liverpool Cancer Trials Unit
University of Liverpool
1st floor Block C
Waterhouse Building
3 Brownlow Street
L69 3GL
United Kingdom

Additional identifiers

EudraCT number

2014-004437-22 number

Protocol/serial number


Study information

Scientific title

A randomised three arm, open label, phase II study of continuous selumetinib versus continuous or interrupted selumetinib in combination with weekly paclitaxel in metastatic uveal melanoma



Study hypothesis

This study aims to compare continuous single agent selumetinib to combination paclitaxel and selumetinib in either a continuous or intermittent schedule.

Ethics approval

London - City & East Research Ethics Committee, 08/04/2015, ref: 15/LO/0159

Study design

Randomised; Interventional; Design type: Treatment

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use contact details to request a participant information sheet


Topic: Cancer; Subtopic: Melanoma; Disease: Melanoma


1. Paclitaxel, IMP
2. Selumetinib, IMP

Intervention type



Phase II

Drug names

Primary outcome measure

Progression Free Survival (PFS) time.; Timepoint(s): Progression

Secondary outcome measures

1. GNAQ/GNA11 mutation status
2. RECIST Response
3. Safety and toxicity

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

Histologically or cytologically confirmed metastatic uveal melanoma
1. Patients must have measurable disease, defined by RECIST 1.1
2. Age at least18 years
3. ECOG performance status 0­2
4. Life expectancy of greater than 3 months
5. Able to swallow and retain orally­administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
6. All prior treatment­related toxicities must be CTCAE v4 grade = 1 (except alopecia) at the time of randomization
7. Laboratory values as listed below (SI units):
7.1. Total bilirubin = 1.5 X institutional upper limit of normal (ULN)
7.2. Aspartate aminotransferase or alanine aminotransferase >2.5 x ULN (or =5 ULN in presence of liver metastases)
7.3. Haemoglobin =9.0 g/dL
7.4. Platelets >100x109/L (100,000 per mm3)
7.5. Absolute neutrophil count >1.5x109/L (1500 per mm3)
7.6. Creatinine = 1.5 mg/dL OR calculated creatinine clearance (Cockroft­Gault formula) =50 mL/min OR 24­hour urine creatinine clearance =50 mL/min
8. Female patients of child­bearing potential should have a negative pregnancy test

Participant type


Age group




Target number of participants

Planned Sample Size: 123; UK Sample Size: 123; Description: 123 evaluable patients will be randomised to arms A, B and C across 13 UK centres. Subjects will be randomised 1:1:1 between the 3 arms.

Participant exclusion criteria

1. Patients may not have received prior chemotherapy for uveal melanoma. This includes patients who have received isolated hepatic perfusion of chemotherapy. Patients who have received prior immunotherapy or non­chemotherapy locoregional therapy for liver metastases, but who have documented evidence of progression of metastatic disease would however be eligible
2. Patients who have a known or suspected brain metastases or spinal cord compression, unless asymptomatic, has been treated with surgery and / or radiation, and has been stable without requiring corticosteroids nor anti­convulsant medications for at least 4 weeks prior to the first dose of study medication
3. Prior exposure to MEK, Ras, or Raf inhibitors or history of hypersensitivity to any excipient agents.
4. History of another malignancy unless disease­free for 3 years. Patients, who have had a completely resected nonmelanoma skin cancer, are eligible
5. Any permitted previous treatment must have been greater than 21 days prior to study treatment starting and all toxicities from previous treatments should have resolved
6. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Treated brain metastases must have been stable for at least 1 month
7. Current use of a prohibited medication
8. Cardiac conditions as follows:
8.1. Uncontrolled hypertension (BP =150/95 mmHg despite medical therapy)
8.2. Acute coronary syndrome within 6 months prior to starting treatment
8.3. Baseline Left ventricular ejection fraction (LVEF) below the LLN or <55% measured by echocardiography or institution’s LLN for MUGA
8.4. Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest
8.5. Symptomatic heart failure NYHA Class II­IV, prior or current cardiomyopathy, or severe valvular heart disease
8.6. Prior or current cardiomyopathy including but not limited to the following:
8.7. Known hypertrophic cardiomyopathy
8.8. Known arrhythmogenic right ventricular cardiomyopathy
8.9. Previous moderate or severe impairment of left ventricular systolic function (LVEF <45% on echocardiography or equivalent on MuGA) even if full recovery has occurred
8.10.Uncontrolled angina (Canadian Cardiovascular Society grade II­IV despite medical therapy)
8.11. Acute coronary syndrome within 6 months prior to starting treatment
8.12. QTcF >450ms or other factors that increase the risk of QT prolongation
9. Ophthalmological conditions as follows (unless in the eye involved by uveal melanoma):
9.1. Intra­ocular pressure >21 mmHg, or uncontrolled glaucoma (irrespective of intra­ocular pressure)
9.2. Current or past history of retinal pigment epithelial detachment (RPED)/central serous retinopathy(CSR) or retinal vein occlusion
10. Uncontrolled intercurrent illness or uncontrolled systemic disease including, but not limited to, ongoing or active infection – including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), symptomatic congestive heart failure, unstable/uncontrolled angina pectoris, uncontrolled cardiac arrhythmia, QTc prolongation, active bleeding diatheses, renal transplant or psychiatric illness/social situations that would limit compliance with study requirements
11. Female patients who are breast­feeding
12. Male or female patients of reproductive potential who are not employing an effective method of contraception

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Liverpool Cancer Trials Unit
Cancer Research UK Liverpool Cancer Trials Unit University of Liverpool 1st Floor Block C, Waterhouse Building 3 Brownlow Street
L69 3GL
United Kingdom

Sponsor information


University of Liverpool

Sponsor details

Cancer Research UK Liverpool Cancer Trials Unit
University of Liverpool
1st floor Block C
Waterhouse Building
3 Brownlow Street
L69 3GL
United Kingdom

Sponsor type




Funder type


Funder name


Alternative name(s)

AstraZeneca PLC

Funding Body Type

private sector organisation

Funding Body Subtype

For-profit companies (industry)


United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer reviewed journal

IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date

Intention to publish date


Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

21/02/2019: Publication and dissemination plan and IPD sharing statement added. 18/02/2019: The following changes were made to the trial record: 1. The recruitment end date was changed from 01/02/2018 to 28/11/2018. 2. The overall trial end date was changed from 01/02/2018 to 01/07/2019. 02/02/2016: Link to lay summary added.